ICAP

PURPOSE 3/HPTN 102 Study

A Phase 2, open-label, multicenter, randomized study to evaluate the pharmacokinetics, safety, and acceptability of twice-yearly long-acting subcutaneous lenacapavir for pre-exposure prophylaxis in cisgender women in the United States.


https://www.avac.org/trial/purpose-3-hptn-102

Status

Upcoming

Locations

Our Approach

Research

Health Challenges